From the other side of the consultation, briefly. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.
GenomicsKate said:The mechanism and the magnitude are separate questions.
Adding a me-too, because a thread of one person's experience is not much use. Posting only so the count is not one.
GenomicsKate said:The mechanism and the magnitude are separate questions.
Coming at GenomicsKate’s question from a different direction. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemOne concrete data point for the thread. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.
Worth separating that from retatrutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
Following on from GenomicsKate — and this may be the naive question:
Why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose?